Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexpropranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL10537386 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL1561135 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL12264958 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL3956 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL3955 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL25255 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL29355940 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL6511347 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL22291223 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL20486000 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| US-12290765-B2 | Materials and methods for processing blood samples | NATERA, INC. (US) | 2025-05-06 | — | — | US | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| CN-118164862-B | Coupling separation method for efficient crystallization resolution of propranolol enantiomer and mother liquor in-situ regeneration and reuse of propranolol enantiomer | 湖南科技大学 | 2025-01-28 | — | — | CN | claimed |
| US-20240350945-A1 | MATERIALS AND METHODS FOR PROCESSING BLOOD SAMPLES | NATERA, INC. (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-117731779-A | Use of Lipin1 inhibitors for the prevention or treatment of viral infections | 北京大学 | 2024-03-22 | — | — | CN | claimed |
| US-11931674-B2 | Materials and methods for processing blood samples | NATERA, INC. (US) | 2024-03-19 | — | — | US | claimed |
| WO-2023198107-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTION | PEKING UNIVERSITY (CN) | 2023-10-19 | — | — | WO | claimed |
| US-20230019159-A1 | RAPID DRUG DISCOVERY METHODS FOR PATHOGEN INACTIVATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2023-01-19 | — | — | US | claimed |
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | NOVARTIS PHARMA AG (CH) | 2026-04-23 | — | — | US | disclosed |
| US-12533340-B2 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | NOVARTIS AG (CH) | 2026-01-27 | — | — | US | disclosed |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | DHANOA DALJIT SINGH (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250224371-A1 | METHOD OF DETERMINING THE ENANTIOMERIC PURITY OF AN ANALYTE | MICROMASS UK LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-11384332-B2 | Bacillus megaterium bioactive compositions and metabolites | MARRONE BIO INNOVATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382328-B2 | Rapid drug discovery methods for pathogen inactivation | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| EP-4008403-A1 | CYCLIC DI-NUCLEOTIDES COMPOUNDS FOR THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| US-11351169-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-11339188-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | PMP22, PSMB2, SMN1; SMN2 | ADRB2 43/4885ADRB1 214/4885CYP2D6 4221/4885 |
| US-11339188-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | ADRB2 4482/4885ADRB1 4383/4885CYP2D6 2793/4885 |
| US-12533340-B2 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | SCN2B, SCN1B, ADRB2 | ADRB2 3/4885ADRB1 18/4885CYP2D6 1569/4885 |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | AGTR2, AGTR1, EDNRA | ADRB2 69/4885ADRB1 56/4885CYP2D6 473/4885 |
| US-11351169-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | ADRB2 1159/4885ADRB1 2188/4885CYP2D6 943/4885 |
| US-11384332-B2 | Bacillus megaterium bioactive compositions and metabolites | GZMB, VIP, BAX | ADRB2 1010/4885ADRB1 1244/4885CYP2D6 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.